Compare Ascendis Pharma A/S (ASND) vs VanEck Junior Gold Miners (GDXJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs VanEck Junior Gold Miners — how do they compare? Ascendis Pharma A/S trades at $263.15 (market cap $17.74B), while VanEck Junior Gold Miners trades at $96.11. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals.
| ASND | GDXJ | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $277.18 | $156.19 |
52-Week Low | $163.32 | $64.22 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
GDXJ trades at $98.91, down 0.06% on the day, with a bearish technical outlook as moving averages signal selling pressure and key support lies at $97. The ETF has underperformed peers in 2026, with Seeking Alpha noting double-digit declines amid concerns over its small-cap exposure and portfolio overlap. Recent news highlights investor caution toward junior gold miners compared to senior counterparts.
The investment case remains challenged by weak sentiment and technical headwinds, though potential exists as a hedge during market corrections. Risks include Federal Reserve policy impacts on gold prices and competition from other mining ETFs. Wall Street sentiment is cautious, with no bullish analyst signals evident in recent data.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →
